ARTHROPLASTY, REPLACEMENT
14
2
2
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
7.1%
1 terminated out of 14 trials
90.0%
+3.5% vs benchmark
14%
2 trials in Phase 3/4
44%
4 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
American Joint Replacement Registry
SMR Stemless Reverse Vs SMR Reverse Shoulder System
Patient-Centered Weight Loss Program for Knee Replacement Patients
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
The Impact of Medicare Bundled Payments
Efficacy of Surgical Preparation Solutions in Knee Surgery
An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
Effectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
Wound Additives in Primary Total Joint Athroplasty
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)